粒细胞-巨噬细胞集落刺激因子联合放疗研究进展

张佳奇; 赵路军; 刘宁波; 王平

doi:10.3969/j.issn.1000-8179.2018.09.294

粒细胞-巨噬细胞集落刺激因子联合放疗研究进展

doi: 10.3969/j.issn.1000-8179.2018.09.294

天津医科大学肿瘤医院放射治疗科，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤临床医学研究中心（天津市300060）

基金项目:

国家自然科学基金项目 81372429

详细信息

作者简介:
张佳奇专业方向为肿瘤放射治疗学。E-mail：1151214610@qq.com

通讯作者:
王平 wangping@tjmuch.com

计量
- 文章访问数: 82
- HTML全文浏览量: 7
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2017-11-21
- 修回日期: 2018-03-22
- 刊出日期: 2018-05-15

Advances of granulocyte-macrophage colony-stimulating factor combinied with radiotherapy

Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

Funds:

National Natural Science Foundation of China 81372429

More Information

Corresponding author: Ping Wang; E-mail: wangping@tjmuch.com

摘要

摘要: 粒细胞-巨噬细胞集落刺激因子（granulocyte-macrophage colony-stimulating factor，GM-CSF）作为一种造血因子可以有效诱导多种具有抑瘤效应的免疫细胞增殖，从而发挥抗肿瘤免疫反应。放疗作为肿瘤治疗的主要手段之一，不仅可以直接杀伤肿瘤细胞，而且会对抗肿瘤免疫产生影响。多项临床研究提示，放疗联合GM-CSF可以诱导产生旁观者效应并增强对肿瘤的远期控制，从而增强放疗的抗肿瘤效应。本文就GM-CSF及GM-CSF联合放疗的研究进展予以综述。
- 粒细胞-巨噬细胞集落刺激因子 /
- 放射治疗 /
- 免疫
Abstract: The granulocyte-macrophage colony-stimulating factor (GM-CSF) can effectively induce the proliferation of tumor-associated immunocytes as a hematopoietic factor; therefore, the fact that GM-CSF can induce systemic antitumor immune responses has attracted much attention. Radiotherapy, as one of the main treatment approaches of cancer, can kill tumor cells directly, and has an effect on anti-tumor immunity. Several clinical studies have shown that radiotherapy combined with the GM-CSF can induce an abscopal effect and confer favorable therapeutic effects for cancer. Herein, we review the research progress on GM-CSF, and radiotherapy combined with GM-CSF in tumor treatment.
- granulocyte-macrophage colony-stimulating factor /
- radiotherapy /
- immune

HTML全文

参考文献(34)

[1]	Rosas M, Gordon S, Taylor PR. Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice[J]. Eur J Immunol, 2007, 37(9):2518-2528. doi: 10.1002/(ISSN)1521-4141
[2]	Hercus TR, Broughton SE, Ekert PG, et al. The GM-CSF receptor family: mechanism of activation and implications for disease[J]. Growth Factors, 2012, 30(2):63-75. doi: 10.3109/08977194.2011.649919
[3]	Liu X, Hu J, Cao W, et al. Effects of two different immunotherapies on triple negative breast cancer in animal model[J]. Cell Immunol, 2013, 284(1-2):111-118. doi: 10.1016/j.cellimm.2013.07.018
[4]	RaziSoofiyani S, Kazemi T, Lotfipour F, et al. The effects of gene therapy with granulocyte-macrophage colony-stimulating factor in the regression of tumor masses in fibrosarcoma mouse model[J]. J Cancer Res Ther, 2017, 13(2):362-366. doi: 10.4103/0973-1482.159083
[5]	朱曦龄, 黎功.放疗与免疫治疗协同作用的研究进展[J].中华放射肿瘤学杂志, 2017, 26(10):1227-1230. doi: 10.3760/cma.j.issn.1004-4221.2017.10.025
[6]	Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type Ⅰ interferon-dependent innate and adaptive immunity[J]. Cancer Res, 2011, 71(7):2488-2496. doi: 10.1158/0008-5472.CAN-10-2820
[7]	Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumorspecific effector CD8⁺T cells via dendritic cell activation[J]. J Immunol, 2012, 189(2):558-566. doi: 10.4049/jimmunol.1200563
[8]	Schaue D, Ratikan JA, Iwamoto KS, et al. Maximizing tumor immunity with fractionated radiation[J]. Int J Radiat Oncol Biol Phys, 2012, 83(4):1306-1310. doi: 10.1016/j.ijrobp.2011.09.049
[9]	Hu ZI, Ho AY, McArthur HL. Combined radiation therapy and immune checkpoint blockade therapy for breast cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(1):153-164. doi: 10.1016/j.ijrobp.2017.05.029
[10]	Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy[J]. Trends Cancer, 2016, 2(6):286-294. doi: 10.1016/j.trecan.2016.05.002
[11]	Lugade AA, Sorensen EW, Gerber SA, et al. Radiation-induced IFNgamma production within the tumor microenvironment influences antitumor immunity[J]. J Immunol, 2008, 180(5):3132-3139. doi: 10.4049/jimmunol.180.5.3132
[12]	Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumorspecific effector CD8⁺T cells via dendritic cell activation[J]. J Immunol, 2012, 189(2):558-566. doi: 10.4049/jimmunol.1200563
[13]	Liujarin X, Stoopler MB, Raftopoulos H, et al. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy[J]. Mod Pathol, 2003, 16(11):1102-1108. doi: 10.1097/01.MP.0000096041.13859.AB
[14]	Romo N, Magri G, Muntasell A, et al. Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization[J]. J Leukoc Biol, 2011, 90(4): 717-726. doi: 10.1189/jlb.0311171
[15]	Dranoff G. GM-CSF-based cancer vaccines[J]. Immunol Rev, 2002, (188):147-154. http://www.ncbi.nlm.nih.gov/pubmed/12445288
[16]	Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present and future[J]. Adv Cancer Res, 2013, (119):421-475. http://www.ncbi.nlm.nih.gov/pubmed/23870514
[17]	Deng G, Hu P, Zhang J, et al. Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer[J]. Oncotarget, 2016, 7(51):85142-85150. http://www.ncbi.nlm.nih.gov/pubmed/27835886
[18]	Lumniczky K, Desaknai S, Mangel L, et al. Local tumor irradiation augments the anti-tumor effect of cytokine producing autologous cancer cell vaccines in a murine glioma model[J]. Eur J Cancer, 2001, 37(1):44-52. http://www.ncbi.nlm.nih.gov/pubmed/11916244/
[19]	Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proofof-principle trial[J]. Lancet Oncol, 2015, 16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6
[20]	Shi F, Wang X, Teng F, et al. Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy[J]. Cancer Biol Ther, 2017, 18(3):137-141. doi: 10.1080/15384047.2016.1276133
[21]	Panje C, Guckenberger M. Abskopale effekte der lokalen radiotherapie in kombination mit systemischer Immuntherapie bei patienten mit metastasierten soliden Tumoren[J]. Strahlentherapie Und Onkologie, 2016, 192(1):72-74. doi: 10.1007/s00066-015-0921-4
[22]	Harrington KJ, Hingorani M, Tanay MA, et al. PhaseⅠ/Ⅱstudy of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage Ⅲ/Ⅳ squamous cell cancer of the head and neck[J]. Clin Cancer Res, 2010, 16(15):4005-4015. doi: 10.1158/1078-0432.CCR-10-0196
[23]	Clive KS, Tyler JA, Clifton GT, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental[J]? Exp Rev Vaccines, 2010, 9(5):519-525. doi: 10.1586/erv.10.40
[24]	Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients[J]. Ann Oncol, 2007, 18(2):226-232. http://www.ncbi.nlm.nih.gov/pubmed/17116643
[25]	Li J, Bouton-Verville H, Holmes LM, et al. Inhibition or promotion of tumor growth by granulocyte-macrophage colony stimulating factor derived from engineered tumor cells is dose-dependent[J]. Anticancer Res, 2004, 24(5A):2717. https://www.researchgate.net/profile/Hilary_Bouton-Verville/publication/8202305_Inhibition_or_promotion_of_tumor_growth_by_granulocyte-macrophage_colony_stimulating_factor_derived_from_engineered_tumor_cells_is_dose-dependent/links/09e415081751ce1ded000000.pdf?origin=publication_list
[26]	Triozzi PL, Achberger S, Aldrich W, et al. Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor[J]. J Immun, 2012, 35(7):587-594. doi: 10.1097/CJI.0b013e31826b20b6
[27]	Bayne L, Beatty G, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer[J]. Cancer Cell, 2012, 21 (6):822-835. doi: 10.1016/j.ccr.2012.04.025
[28]	Pylayeva-Gupta Y, Lee KE, Hajdu CH, et al. Oncogenic kras-induced GM-CSF production promotes the development of pancreatic neoplasia[J]. Cancer Cell, 2012, 21(6):836-847. doi: 10.1016/j.ccr.2012.04.024
[29]	姜南雁, 唐隽, 徐云升.GM-CSF在肿瘤免疫治疗中的作用最新研究进展[J].免疫学杂志, 2015, (8):717-722. http://www.cnki.com.cn/Article/CJFDTOTAL-MYXZ201508015.htm
[30]	Bambury RM, Teo MY, Power DG, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme[J]. J Neurooncol, 2013, 114(1): 149-154. doi: 10.1007/s11060-013-1164-9
[31]	陆意, 黄闽杰, 仇建波, 等.立体定向放疗联合免疫治疗晚期恶性肿瘤进展[J].中华放射肿瘤学杂志, 2017, 26(10):1214-1217. doi: 10.3760/cma.j.issn.1004-4221.2017.10.022
[32]	Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment-tumorigenesis and therapy[J]. Nat Rev Cancer, 2005, 5 (11):867-875. doi: 10.1038/nrc1735
[33]	Qu Y, Zhang B, Liu S, et al. 2-Gy whole-body irradiation significantly alters the balance of CD4⁺CD25⁺ T effector cells and CD4⁺CD25⁺Foxp3⁺T regulatory cells in mice[J]. Cell Mol Immun, 2010, 7(6):419. doi: 10.1038/cmi.2010.45
[34]	Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J]. Nat Med, 2007, 13(9):1050. doi: 10.1038/nm1622